OP0202 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: opal beyond, a randomised, double-blind, placebo-controlled, phase 3 trial

Abstract

BackgroundTofacitinib is an oral Janus kinase inhibitor under investigation for treatment of PsA.ObjectivesEvaluation of efficacy and safety of tofacitinib vs placebo (PBO) in adult patients (pts) with active PsA and...